The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic

MOC is a rare histotype of epithelial ovarian cancer, and current management options are inadequate for the treatment of late stage or recurrent disease. A shift towards personalised medicines in ovarian cancer is being observed, with trials targeting specific molecular pathways, however, MOC lags d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arkan Youssef, Mohammad B. Haskali, Kylie L. Gorringe
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	mucinous ovarian cancer theranostics targeted therapy personalised medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0791ac7552304fc39602d787ea7987a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0791ac7552304fc39602d787ea7987a2
record_format	dspace
spelling	oai:doaj.org-article:0791ac7552304fc39602d787ea7987a22021-11-25T17:01:04ZThe Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic10.3390/cancers132255962072-6694https://doaj.org/article/0791ac7552304fc39602d787ea7987a22021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5596https://doaj.org/toc/2072-6694MOC is a rare histotype of epithelial ovarian cancer, and current management options are inadequate for the treatment of late stage or recurrent disease. A shift towards personalised medicines in ovarian cancer is being observed, with trials targeting specific molecular pathways, however, MOC lags due to its rarity. Theranostics is a rapidly evolving category of personalised medicine, encompassing both a diagnostic and therapeutic approach by recognising targets that are expressed highly in tumour tissue in order to deliver a therapeutic payload. The present review evaluates the protein landscape of MOC in recent immunohistochemical- and proteomic-based research, aiming to identify potential candidates for theranostic application. Fourteen proteins were selected based on cell membrane localisation: HER2, EGFR, FOLR1, RAC1, GPR158, CEACAM6, MUC16, PD-L1, NHE1, CEACAM5, MUC1, ACE2, GP2, and PTPRH. Optimal proteins to target using theranostic agents must exhibit high membrane expression on cancerous tissue with low expression on healthy tissue to afford improved disease outcomes with minimal off-target effects and toxicities. We provide guidelines to consider in the selection of a theranostic target for MOC and suggest future directions in evaluating the results of this review.Arkan YoussefMohammad B. HaskaliKylie L. GorringeMDPI AGarticlemucinous ovarian cancertheranosticstargeted therapypersonalised medicineNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5596, p 5596 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mucinous ovarian cancer theranostics targeted therapy personalised medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	mucinous ovarian cancer theranostics targeted therapy personalised medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Arkan Youssef Mohammad B. Haskali Kylie L. Gorringe The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic
description	MOC is a rare histotype of epithelial ovarian cancer, and current management options are inadequate for the treatment of late stage or recurrent disease. A shift towards personalised medicines in ovarian cancer is being observed, with trials targeting specific molecular pathways, however, MOC lags due to its rarity. Theranostics is a rapidly evolving category of personalised medicine, encompassing both a diagnostic and therapeutic approach by recognising targets that are expressed highly in tumour tissue in order to deliver a therapeutic payload. The present review evaluates the protein landscape of MOC in recent immunohistochemical- and proteomic-based research, aiming to identify potential candidates for theranostic application. Fourteen proteins were selected based on cell membrane localisation: HER2, EGFR, FOLR1, RAC1, GPR158, CEACAM6, MUC16, PD-L1, NHE1, CEACAM5, MUC1, ACE2, GP2, and PTPRH. Optimal proteins to target using theranostic agents must exhibit high membrane expression on cancerous tissue with low expression on healthy tissue to afford improved disease outcomes with minimal off-target effects and toxicities. We provide guidelines to consider in the selection of a theranostic target for MOC and suggest future directions in evaluating the results of this review.
format	article
author	Arkan Youssef Mohammad B. Haskali Kylie L. Gorringe
author_facet	Arkan Youssef Mohammad B. Haskali Kylie L. Gorringe
author_sort	Arkan Youssef
title	The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic
title_short	The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic
title_full	The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic
title_fullStr	The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic
title_full_unstemmed	The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic
title_sort	protein landscape of mucinous ovarian cancer: towards a theranostic
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0791ac7552304fc39602d787ea7987a2
work_keys_str_mv	AT arkanyoussef theproteinlandscapeofmucinousovariancancertowardsatheranostic AT mohammadbhaskali theproteinlandscapeofmucinousovariancancertowardsatheranostic AT kylielgorringe theproteinlandscapeofmucinousovariancancertowardsatheranostic AT arkanyoussef proteinlandscapeofmucinousovariancancertowardsatheranostic AT mohammadbhaskali proteinlandscapeofmucinousovariancancertowardsatheranostic AT kylielgorringe proteinlandscapeofmucinousovariancancertowardsatheranostic
_version_	1718412755263815680

The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic

Ejemplares similares